Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Artery | 5 | 2020 | 519 | 1.210 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 3 | 2019 | 34 | 1.210 |
Why?
|
| Hypertension, Pulmonary | 5 | 2020 | 463 | 1.070 |
Why?
|
| Vasoconstriction | 4 | 2020 | 119 | 0.870 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 14 | 0.860 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 183 | 0.590 |
Why?
|
| Patient Admission | 1 | 2017 | 230 | 0.520 |
Why?
|
| rho-Associated Kinases | 1 | 2014 | 74 | 0.460 |
Why?
|
| Veterans | 2 | 2023 | 1735 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 513 | 0.440 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 261 | 0.430 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 1061 | 0.410 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2009 | 262 | 0.400 |
Why?
|
| Inclusion Bodies | 2 | 2009 | 87 | 0.400 |
Why?
|
| Heart Diseases | 1 | 2017 | 718 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3398 | 0.340 |
Why?
|
| Ventricular Function, Right | 2 | 2019 | 115 | 0.260 |
Why?
|
| DNA | 1 | 2014 | 3046 | 0.260 |
Why?
|
| Stress, Physiological | 1 | 2009 | 491 | 0.250 |
Why?
|
| Lung Diseases | 1 | 2011 | 751 | 0.250 |
Why?
|
| Autophagy | 1 | 2011 | 910 | 0.240 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 77 | 0.240 |
Why?
|
| Alanine | 2 | 2021 | 242 | 0.230 |
Why?
|
| Antiviral Agents | 2 | 2021 | 1251 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 4118 | 0.220 |
Why?
|
| Double-Blind Method | 3 | 2021 | 2586 | 0.190 |
Why?
|
| Phenylephrine | 2 | 2019 | 53 | 0.190 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 140 | 0.180 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 528 | 0.180 |
Why?
|
| Hydra | 1 | 2020 | 4 | 0.180 |
Why?
|
| Pulmonary Fibrosis | 2 | 2019 | 175 | 0.180 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 84 | 0.180 |
Why?
|
| Endothelium | 1 | 2020 | 155 | 0.170 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 92 | 0.170 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2019 | 41 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 134 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 173 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 165 | 0.150 |
Why?
|
| Male | 14 | 2023 | 127917 | 0.150 |
Why?
|
| Cells, Cultured | 2 | 2019 | 5658 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2014 | 874 | 0.130 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 698 | 0.130 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2020 | 386 | 0.130 |
Why?
|
| Action Potentials | 1 | 2019 | 596 | 0.130 |
Why?
|
| Emphysema | 1 | 2015 | 88 | 0.120 |
Why?
|
| Aged | 7 | 2023 | 73127 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 2056 | 0.120 |
Why?
|
| Echocardiography | 2 | 2019 | 1223 | 0.120 |
Why?
|
| Heart Atria | 1 | 2017 | 349 | 0.120 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2014 | 21 | 0.120 |
Why?
|
| Vascular Remodeling | 3 | 2020 | 49 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 296 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2019 | 832 | 0.110 |
Why?
|
| Cytokines | 2 | 2015 | 2810 | 0.110 |
Why?
|
| Hypoxia | 1 | 2016 | 471 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 624 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1540 | 0.100 |
Why?
|
| Protein Transport | 3 | 2009 | 737 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 7038 | 0.100 |
Why?
|
| Vasodilation | 1 | 2013 | 216 | 0.100 |
Why?
|
| Disease Progression | 3 | 2020 | 6840 | 0.100 |
Why?
|
| Mice | 7 | 2019 | 35465 | 0.100 |
Why?
|
| Humans | 17 | 2023 | 270033 | 0.090 |
Why?
|
| Female | 10 | 2023 | 148486 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 121 | 0.090 |
Why?
|
| Animals | 9 | 2020 | 61714 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 2389 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2014 | 5694 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2023 | 9464 | 0.090 |
Why?
|
| Pneumonia | 2 | 2014 | 795 | 0.090 |
Why?
|
| Prevalence | 1 | 2017 | 3351 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7343 | 0.080 |
Why?
|
| Rhodamines | 1 | 2009 | 48 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4463 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 859 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 208 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2009 | 1801 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 1559 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2021 | 1425 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 12508 | 0.070 |
Why?
|
| Adult | 7 | 2023 | 81689 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2023 | 39736 | 0.070 |
Why?
|
| Bronchi | 1 | 2009 | 324 | 0.070 |
Why?
|
| Incidence | 1 | 2017 | 5806 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 488 | 0.070 |
Why?
|
| Smoking | 1 | 2015 | 2548 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 4249 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 2325 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2009 | 659 | 0.060 |
Why?
|
| Middle Aged | 5 | 2021 | 90030 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 3939 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cell Survival | 1 | 2009 | 3056 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1867 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 57 | 0.050 |
Why?
|
| Lung | 3 | 2020 | 3288 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 2161 | 0.050 |
Why?
|
| Kallikrein-Kinin System | 1 | 2020 | 2 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 32647 | 0.050 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 8 | 0.050 |
Why?
|
| Phenyl Ethers | 1 | 2020 | 9 | 0.050 |
Why?
|
| Clathrin | 1 | 2020 | 36 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2021 | 33691 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2020 | 61 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 105 | 0.040 |
Why?
|
| United States | 1 | 2017 | 15776 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 518 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 4470 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 233 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2019 | 14 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 724 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 593 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2019 | 81 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 171 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 468 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 684 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 482 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 580 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 619 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2014 | 12087 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 1001 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 2207 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 308 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 1036 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 654 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 393 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 68 | 0.030 |
Why?
|
| Calcimycin | 1 | 2013 | 48 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 150 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 68 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2020 | 1560 | 0.030 |
Why?
|
| Indomethacin | 1 | 2013 | 115 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 589 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 892 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 331 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2316 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1603 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 5046 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 904 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1199 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2009 | 109 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2009 | 110 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 269 | 0.020 |
Why?
|
| Detergents | 1 | 2008 | 29 | 0.020 |
Why?
|
| Dyneins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2008 | 51 | 0.020 |
Why?
|
| Histone Deacetylase 6 | 1 | 2008 | 45 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2089 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 267 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 439 | 0.020 |
Why?
|
| Child | 2 | 2023 | 30466 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 773 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3037 | 0.020 |
Why?
|
| Microtubules | 1 | 2008 | 326 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 364 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2008 | 579 | 0.020 |
Why?
|
| Asthma | 1 | 2014 | 894 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2008 | 1077 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 2319 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 1472 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4360 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 809 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 1583 | 0.010 |
Why?
|
| Neoplasms | 1 | 2009 | 15902 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 3477 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 4939 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 3187 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 5336 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 22451 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 6485 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 14832 | 0.010 |
Why?
|